Navigation Links
PharmaNet Development Group Announces Observational Research Survey
Date:10/11/2010

PRINCETON, N.J., Oct. 11 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of drug development services to the pharmaceutical, biotechnology, generic drug and medical device industries announced today the availability of a new survey on pharmaceutical Observational Research, the fourth in an on-going series. The survey is open to all in the industry with an interest in observational research and can be accessed here through October 31, 2010.  

Jeff Trotter,  Executive Vice President, Phase IV Development, and creator of the survey, remarked, "Pharmaceutical companies are increasingly looking to prospective Observational Research for compiling real world data on post-approval clinical performance, economic value, patient quality-of-life, and product safety. While the scientific community excels at designing and executing controlled clinical trials, there may be less appreciation for the value of observational studies. The goal of the survey is to identify underlying issues in order to move toward more appropriately-designed studies that improve the understanding of product performance among clients, regulators, policymakers, physicians and patients."

Previous surveys have revealed that drug development organizations can benefit from broader cross-functional collaboration and consensus on the strategy for observational research. The latest survey will continue to track evolving trends.

The results of this survey, plus the findings identified in previous surveys, are expected to be released in November.  If you are interested in receiving the findings report or receiving more information on pharmaceutical observational research, please contact aserody@pharmanet.com.  

About PharmaNet Development Group, Inc.PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2300 employees in 33 countries and more than 38 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at www.pharmanet.com.  Contact: Anne-Marie HessPhone:   (609) 951-6842E-mail:   ahess@pharmanet.com
'/>"/>

SOURCE PharmaNet Development Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PharmaNet Development Group To Showcase Innovative Solutions and Poster Presentations at AAPS 2009
2. Azopharma and PharmaNet Development Group Enter Preclinical Strategic Alliance
3. PharmaNet Development Group Management Participates in the 8th Annual Partnerships in Clinical Trials Conference in Rotterdam
4. Jeffrey Trotter Joins Pharmanet Development Group as Executive Vice President, Phase IV Development
5. Steven Leventer Joins PharmaNet Development Group as Vice President, Clinical Research Neuroscience
6. PharmaNet Development Group Symposia Crossing the Bridge from Preclinical to Clinical Studies to be Held February 2010 in Basel, Dusseldorf and Vienna
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. Promising Cystic Fibrosis Compound on Track for Development
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... 27, 2016 Global  urinalysis ... billion by 2022, according to a new report ... (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ... efficiency and accuracy delivered by the new generation ... novel urinalysis instruments and consumables. For instance, the ...
(Date:4/27/2016)... -- At the Sachs CEO forum in ... 2 clinical study of its lead drug candidate, STR001, ... (CI) surgery. This large, placebo-controlled, double-blind, phase 2 study ... and France . STR001 is ... of surgery. "Despite advances in cochlear implant technology, a ...
(Date:4/26/2016)... , April 26, 2016 Hill-Rom Holdings, Inc. ... a management presentation at the Deutsche Bank 41 st ... 2:50 p.m. EDT. You are invited to listen ... http://ir.hill-rom.com/events.cfm or access it directly at http://edge.media-server.com/m/p/mr4uxgas . ... hour after conclusion of the live event and accessible at ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... The White House announced efforts ... more information about their loan terms and accounts, and more protections for borrowers. ... federal and private loans, has reached $1.3 trillion, with 43 million Americans holding ...
(Date:4/29/2016)... ... April 29, 2016 , ... A new study by ... congenital diaphragmatic hernia have better survival rates if surgery is performed early. Approximately ... where the diaphragm fails to form completely, letting abdominal organs into the chest ...
(Date:4/29/2016)... ... April 29, 2016 , ... Mobility Designed is redefining mobility ... the armpits, the M+D Crutch evenly distributes body weight from the elbow to the ... when using the crutches than with other crutches. , Co-founders Max and Liliana Younger ...
(Date:4/29/2016)... ... April 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although only about ... of skin cancer deaths. More than 10,000 people are expected to die of melanoma this ... it is the one of the most commonly diagnosed cancers in young women. A recent ...
(Date:4/29/2016)... ... April 29, 2016 , ... Reltok Nasal Products proudly announces that Boston ... and neck/ear, nose and throat specialty, has added the KOTLER NASAL AIRWAY™ to its ... is a newly patented safety device secured by nasal surgeons onto the floor ...
Breaking Medicine News(10 mins):